Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial

Overview of attention for article published in BMC Cancer, June 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (58th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 66 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 6 X posts from 5 X users, with an upper bound of 13,507 followers.

RT @bdermanmd: HRQoL in the ALCYONE trial: - No difference btwn Dara-VMP & VMP - Bar is low for improving QoL w/ induction therapy in myelo…

15 Jun 2021

Reply Repost Favourite

RT @bdermanmd: HRQoL in the ALCYONE trial: - No difference btwn Dara-VMP & VMP - Bar is low for improving QoL w/ induction therapy in myelo…

08 Jun 2021

Reply Repost Favourite

RT @bdermanmd: HRQoL in the ALCYONE trial: - No difference btwn Dara-VMP & VMP - Bar is low for improving QoL w/ induction therapy in myelo…

07 Jun 2021

Reply Repost Favourite

HRQoL in the ALCYONE trial: - No difference btwn Dara-VMP & VMP - Bar is low for improving QoL w/ induction therapy in myeloma. Patients often don't feel good, and quickly recuperate with therapy. - Dara doesn't worsen QoL but does deepen response http

07 Jun 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 2 additional X posts.